Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Telix Pharmaceuticals Limited
ABN	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christian Behrenbruch
Date of last notice	1 June 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	26 October 2026
No. of securities held prior to change	Direct interest: • 654,006 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 93,114 PSARs (notional exercise price $4.95) (TLXO012 – TLXAO) issued following shareholder approval at the AGM held 18 May 2022. • 100,223 PSARs (notional exercise price $6.90) (TLXO015 – TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 PSARs (notional exercise price $11.94) (TLXO024 – TLXAO) issued

+ See chapter 19 for defined terms.

For personal use only

	following shareholder approval at the AGM held 22 May 2024. • 166,483 PSARs (notional exercise price $28.67) (TLXO030 – TLXAO) issued following shareholder approval at the AGM held 21 May 2025. • 2,595 SRs (Nil exercise price) (TLXO031 – TLXAU) issued following shareholder approval at the AGM held 21 May 2025. • 339,845 PSARs (notional exercise price $13.43) issued following shareholder approval at the AGM held 21 May 2026 • 27,121 SRs issued following shareholder approval at the AGM held 21 May 2026 38,750 Indirect interest: • 20,742,935 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).
Class	Ordinary Shares
Number acquired	38,750 Ordinary Shares
Number disposed	NIL
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$12.8935 per Ordinary Share

For personal use only

For personal use only

No. of securities held after change	Direct interest • 654,006 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 93,114 PSARs (notional exercise price $4.95) (TLXO012 – TLXAO) issued following shareholder approval at the AGM held 18 May 2022. • 100,223 PSARs (notional exercise price $6.90) (TLXO015 – TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 PSARs (notional exercise price $11.94) (TLXO024 – TLXAO) issued following shareholder approval at the AGM held 22 May 2024. • 166,483 PSARs (notional exercise price $28.67) (TLXO030 – TLXAO) issued following shareholder approval at the AGM held 21 May 2025. • 2,595 SRs (Nil exercise price) (TLXO031 – TLXAU) issued following shareholder approval at the AGM held 21 May 2025. • 339,845 PSARs (notional exercise price $13.43) issued following shareholder approval at the AGM held 21 May 2026 • 27,121 SRs issued following shareholder approval at the AGM held 21 May 2026 Indirect interest • 20,781,685 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase on ASX

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

+ See chapter 19 for defined terms.